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SUMMARY
Introduction of pneumococcal conjugate and polysaccharide vaccines into the United Kingdom’s
routine immunization programmes is expected to change the epidemiology of invasive
pneumococcal disease (IPD). We have documented the epidemiology of IPD in an English region
(South West) with high-quality surveillance data before these programmes were established.
We analysed data on isolates of Streptococcus pneumoniae from blood and CSF between 1996
and 2005 from microbiology laboratories in the South West that were reported and/or referred
for serotyping to the Health Protection Agency Centre for Infections. The mean annual incidence
of IPD increased from 11.2/100 000 in 1996 to 13.6/100 000 in 2005 (P<0.04). After adjusting for
annual blood-culture sampling rates in hospitals serving the same catchment populations, an
increase in annual incidence of IPD was no longer observed (P=1.0). Variation in overall
incidence between laboratories could also be explained by variation in blood culture rates.
The proportion of disease caused by serotypes 6B, 9V and 14 decreased signiﬁcantly (P=0.001,
P=0.007, and P=0.027 respectively) whereas that caused by serotype 4, 7F and 1 increased
(P=0.001, P=0.003, and P<0.001 respectively) between 2000 and 2005. The level of penicillin
non-susceptibility and resistance to erythromycin remained stable (2% and 12% respectively).
This study provides an important baseline to assess the impact of changing vaccination
programmes on the epidemiology of IPD, thus informing future use of pneumococcal vaccines.
INTRODUCTION
Invasive pneumococcal disease (IPD) is associated
with high morbidity and mortality, especially among
the very young and the elderly [1, 2]. While several
European countries have experienced an increasing
incidence of infections with penicillin-resistant
Streptococcus pneumoniae, others, especially those in
northern Europe, have reported lower levels of re-
sistance [3–6]. Understanding the epidemiology of
IPD is important in the planning, implementation and
evaluation of prevention strategies including vacci-
nation.
Since 2003, the 23-valent pneumococcal poly-
saccharide vaccine (initially recommended in the
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United Kingdom for people at increased risk of
pneumococcal disease [7]), has been recommended
in the United Kingdom for use in all those aged
>65 years. In England and Wales this recommenda-
tion was implemented in a stepwise manner from
2003, initially in those aged o80 years and, then in
those aged o75 years, and ﬁnally for all those aged
o65 years from April 2005. Prior to the introduction
of this policy the 23 serotypes included in the vaccine
accounted for 96% of pneumococcal isolates causing
serious infections in Britain [8].
In 2000, a 7-valent pneumococcal conjugate vaccine
was licensed for children aged<5 years in the United
States and recommended for routine use in children
aged 2–23 months in the same year [9]. In 2002, this
new vaccine was recommended for immunization of
at-risk children aged<2 years in theUnitedKingdom,
extended to at-risk children aged<5 years [7] in 2004
and included in the routine immunization schedule
for children in the United Kingdom in September
2006 [10]. In the United States this vaccine has re-
duced the incidence of IPD due to vaccine serotypes in
vaccinated and unvaccinated individuals including
adults via herd immunity [11].
We undertook this study to describe the epidemi-
ology of IPD in South West England (population 5
million), between 1996 and 2005. (The 23-valent
pneumococcal polysaccharide vaccine, originally
licensed for speciﬁc risk groups in 1989 in England,
was extended in 2003 to include all individuals aged
>65 years but implementation was phased in over
3 years with the inclusion of all individuals aged
>65 years by April 2005.) The main objective was
to provide a baseline for the interpretation of any
changes arising from the new vaccination strategies.
A second objective was to analyse temporal and geo-
graphic variation in IPD incidence.
METHODS
For this study, IPD refers to infection in which
S. pneumoniae is isolated from blood or cerebrospinal
ﬂuid (CSF). Laboratories in England and Wales vol-
untarily report all clinically signiﬁcant bacterial iso-
lates of invasive disease to the Health Protection
Agency Centre for Infections. Episodes in which
S. pneumoniae is isolated from CSF or in blood with a
clinical diagnosis of meningitis are categorized as
pneumococcal meningitis. Each report corresponds
to one patient episode of illness and contains infor-
mation on patient date of birth or age, sex, reporting
laboratory, source of the specimen and antibiotic
susceptibility. A second data source comprises the
IPD isolates referred for serotyping to the HPA’s Res-
piratory and Systemic Infection Laboratory (RSIL)
from laboratories in England and Wales. Not all IPD
isolates sent for serotyping to RSIL are reported to
the HPA database and vice versa. Both data sources
are routinely and regularly reconciled to produce a
single national dataset of IPD cases (see http://
www.hpa.org.uk/infections/topics_az/pneumococcal/
default.htm) from which data for the South West was
extracted for this study.
Microbiology laboratories in the South West sup-
plied the annual number of blood cultures performed
by each laboratory. To analyse geographical vari-
ation, we used laboratory catchment populations
derived from primary-care usage data. Age group-
speciﬁc incidence rates were calculated using national
Census data. We measured incidence trends by means
of negative binomial regression using case data from
laboratories, and adjusting for laboratory catchment
populations and blood cultures. Incidence trends by
age group adjusting for laboratory catchment popu-
lations were also calculated.
IPD isolates referred for serotyping to RSIL were
conﬁrmed as pneumococci and serotyped using
standard methods [12, 13]. Results of antimicrobial
susceptibility testing were incorporated within the
routine surveillance outputs from the participating
laboratories, and the data are summarized on the basis
of the susceptibility test reports issued to clinicians.
Some of the isolates were also susceptibility tested at
the Antimicrobial Resistance Monitoring and Refer-
ence Laboratory at the HPA Centre for Infections by
determination of minimum inhibitory concentration
(MIC). MICs were determined in air on diagnostic
sensitivity test agar (Oxoid, Basingstoke, UK) con-
taining 5% lysed horse blood (TCS Microbiology,
Birmingham, UK) as described previously [14]. Iso-
lates were categorized as susceptible or resistant using
break-points recommended by the British Society for
Antimicrobial Chemotherapy [15].
RESULTS
The annual incidence of IPD in South West England
increased from 11.2/100 000 in 1996 to 13.6/100 000
in 2005 (trend of 1.014 per year, 95% CI 1.001–1.027,
P=0.04, adjusted for population and laboratory
catchment area; Table). There is no evidence to
suggest this increase diﬀers by age group (P=0.28). In
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the <5 years age group the annual incidence in-
creased from 20.8/100 000 in 1996 to 26.3/100 000 in
2005 and in those aged >65 years it changed from
32.5/100 000 to 31.0/100 000. The highest annual age-
speciﬁc attack rates were seen in age groups<5 years
and >65 years (mean 22.8/100 000 and 31.2/100 000)
(Fig. 1). The male :female ratio was 1.1:1. The aver-
age incidence of IPD by laboratory catchment popu-
lation ranged from 8.6–18.7/100 000 (Table). A stable
seasonal pattern, with increased incidence in winter
months was seen throughout the study period. The
numbers of IPD cases reached a low during August
and peaked in December and January when numbers
were 3–5 times higher.
Adjusting annual IPD incidence by annual blood-
culture sampling rates removed evidence of an in-
creasing trend (trend of 1.000 per year, 95% CI
0.984–1.016, P=1.0, adjusted for population, lab-
oratory catchment area and annual blood-culture
sampling rates). The 10-year incidence of IPD by
catchment population was also associated with
blood-culture sampling rates (P<0.001), i.e. labora-
tories serving populations with higher IPD incidence
were also found to have higher blood-culture sam-
pling rates (Fig. 2).
Of all isolates, 394 (6.9%) were from cases of
pneumococcal meningitis. The mean annual incidence
of meningitis was 0.8/100 000 population (all ages).
No discernible trend was observed for pneumococcal
meningitis over the study period (P=0.136). Of all
the meningitis cases, 24.5% occurred in patients aged
<1 year.
Serotype distribution
The proportion of invasive isolates with serotype in-
formation rose steadily from 39% in 1996 to 77%
in 2005, compared with a mean change of 35–67%
for the other English regions. Analysis of serotype
distribution was restricted to the 6 years between 2000
and 2005 when serotype information was available for
at least 50% of isolates. Fifty-four diﬀerent serotypes
Table. IPD isolates in the South West of England by year 1996–2005
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
IPD 543 588 447 496 537 584 559 616 634 689
Cultures 102 772 105 974 108 788 112 611 113 620 122 200 134 683 143 339 140 123 153 335
South West
population
4 841 545 4 875 973 4 901 316 4 935 669 4 975 091 4 934 162 4 959 593 4 999 287 5 038 200 5 067 794
IPD/100 000 pop. 11.2 12.1 9.1 10.0 10.8 11.8 11.3 12.3 12.6 13.6
Cultures/
100 000 pop.
2123 2173 2220 2282 2284 2477 2716 2867 2781 3026
IPD, Invasive pneumococcal disease.
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Fig. 1. Invasive pneumococcal disease (IPD) in the South West of England by year 1996–2005, by age group.%, IPD (all)/
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were detected in this 6-year period. There was signiﬁ-
cant variation in pneumococcal disease caused by
the diﬀerent serotypes in these 6 years (P<0.001). The
proportion of disease caused by serotypes 6B, 9V and
14 decreased signiﬁcantly (P=0.001, P=0.007, and
P=0.027 respectively) whereas that caused by sero-
types 4, 7F and 1 increased (P=0.001, P=0.003 and
P<0.001 respectively) (Fig. 3).
The most common serotypes in all ages were 14, 1,
9V, 23F, 8, and 4. In those aged <5 years, the most
common serotypes were 14, 6B, 19F, 18C and 1. The
7-valent conjugate vaccine contains serotypes corre-
sponding to 248/341 (73%) known serotypes causing
IPD in this age group. The most important serotypes
causing illness and not included in the 7-valent con-
jugate were serotypes 1, 19A, 6A, and 7F, responsible
for 17% of invasive infections. In those aged >65
years, the most common serotypes were 14, 23F, 9V,
3, and 6B. In this age group, 90% of the serotypes
causing illness were contained in the 23-valent poly-
saccharide vaccine compared with 58% of serotypes
in the 7-valent vaccine.
Antimicrobial susceptibility
Antimicrobial susceptibility data for erythromycin
and penicillin were available for 74% and 82% of iso-
lates between 1996 and 2005. The availability of anti-
microbial resistance results reported through routine
surveillance improved steadily from 1996, rising from
52% to 87% for penicillin and from 51% to 84% for
erythromycin. The proportions of strains resistant to
erythromycin and penicillin non-susceptible remained
similar between 1996 and 2005 (mean 12.0% and
1.8% respectively). Of the 248 invasive infections in
<5-year-olds caused by serotypes contained in the
7-valent conjugate vaccine, 21% were resistant to
erythromycin (mainly serotype 14), compared with
6% due to serotypes not in the vaccine (P=0.002).
There was no diﬀerence in the equivalent proportions
non-susceptible to penicillin.
DISCUSSION
This paper sets out a 10-year baseline of high-quality
surveillance data from an English region to interpret
changes in the epidemiology of IPD following recent
changes to routine vaccination programmes in the
United Kingdom. The 5693 isolates from the South
West reported to the national enhanced surveillance
system accounted for 10% of isolates in England and
Wales during the same period [16]. Although the in-
cidence of IPD increased signiﬁcantly over the study
period, this could be explained by an increase in the
rate of blood culture sampling. Similarly, higher rates
of blood culture sampling were associated with higher
incidence by laboratory catchment population, con-
sistent with ﬁndings of Smith et al. [17]. The rate of
blood culture sampling should therefore be taken
into account in any evaluation of the impact of vac-
cination programmes.
In common with other reports, IPD exhibited dis-
tinct winter seasonality in all areas in the South West,
and over all the years investigated [18]. This seasonal
ﬂuctuation in the incidence of IPD has been at-
tributed to exposure to winter viruses (e.g. inﬂuenza
and respiratory syncytial virus) [19] and to tempera-
ture [20]. The higher incidences seen in the 1996–1997
and 1999–2000 seasons might have been related to
the peaks of inﬂuenza seen in those seasons [21]. A
recent study by Hussain et al. showed that there were
no signiﬁcant seasonal diﬀerences in the prevalence of
carriage of S. pneumoniae [22].
Across Europe, diﬀerences in the incidence of IPD
have been well documented. These can be explained
to varying extents by patient and health-care factors
such as blood culture practice and pre-admission
antibiotic administration [23], as well as wide vari-
ations in surveillance systems [24]. In periods of
changes in vaccination policy, surveillance needs to
take these factors into consideration when evaluating
changes in incidence trends.
Although vaccination in those agedo65 years was
only recommended in the United Kingdom in 2003,
primary-care physicians had already been advised to
immunize certain high-risk patients. With a reported
eﬃcacy against invasive disease of about 65% [25],
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Fig. 2. Relationship between rate of invasive pneumococcal
disease (IPD) and blood culture per 100 000 population
in the South West of England by laboratory and year,
1996–2005.
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good surveillance data is essential in showing an eﬀect
of the introduction of the vaccine at a population
level. While the protective eﬃcacy of this vaccine for
the growing population of adults aged >65 years
has been shown, its limited protective eﬀect on
non-invasive disease has led to some controversy
about its overall impact at the population level [26].
Pneumococcal polysaccharide vaccine (PPV) uptake
in the>65 years age group was 64.4% nationally by
April 2006 [27]. No reduction in IPD incidence in
older age groups was seen between 2003 and 2005 in
our study, the last 2 years of which overlaps with
the stepped introduction of the PPV programme for
the elderly in 2003.
On the other hand, there is a growing body of evi-
dence supporting the beneﬁcial eﬀects of the conju-
gate pneumococcal vaccine. In the United States,
from 1998 to 2003, the incidence of IPD associated
with serotypes contained within the 7-valent conju-
gate vaccine decreased by 94%, and by 75% overall
[28]. The data contained in our study and further
surveillance data will enable the elicitation of similar
evidence from our setting.
Resistance to antimicrobials used in the treatment
of IPD is of continuing concern. Nationally, penicillin
non-susceptibility rates vary between regions from
a low of 3% in South West in 1999 compared to a
high of 11% in London [18]. Our results show that
rates of resistance to erythromycin and penicillin
non-susceptibility have remained stable and resistance
patterns did not vary geographically in the South
West region over recent years. The relatively high level
of resistance to erythromycin that we found is also
reﬂected in the national dataset and reinforces the
unreliability of macrolides as empirical monotherapy
for suspected pneumococcal infections. Among the
potential beneﬁts of the introduction of the 7-valent
conjugate vaccines to the vaccination schedule in the
United Kingdom includes a possible reduction in the
incidence of macrolide and penicillin resistance, since
the vaccine covers the majority of antibiotic-resistant
pneumococci. Such reductions have been reported in
the United States where the vaccine was introduced
in 2000 [29].
At least 90 pneumococcal serotypes have been re-
cognized to date, but only a small proportion of these
serotypes are commonly associated with IPD [30]. All
three serotypes that showed a signiﬁcant reduction
in incidence and one that showed an increase are
included in the 7-valent conjugate vaccine. These
changes occurred before the introduction of this vac-
cine into the routine childhood vaccination pro-
gramme. Continued surveillance of the distribution of
pneumococcal serotypes causing invasive disease
permits the evaluation of the impact of such vaccines,
as well as providing early warning of the emergence
of non-vaccine serotypes as causes of invasive dis-
ease [31]. The high level of erythromycin resistance
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among serotypes contained in the conjugate vaccine
suggests that this vaccine may reduce the level of such
resistance, both in children and through herd im-
munity in older populations. Some herd immunity in
adults following introduction of conjugate vaccine
in childhood is expected, but the limited impact of
polysaccharide vaccination on pneumococcal disease
in the elderly means that the use of conjugate vaccines
in this age group may yet prove a cost-eﬀective public
health intervention.
APPENDIX
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Mike Smith (Chairman up to 2004) (Taunton &
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